Figure 1 | Scientific Reports

Figure 1

From: Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

Figure 1

mRNA expression of IL-32 isoforms IL-32β, IL-32γ, in RA patients and healthy individuals in (un)stimulated PBMCs also separated on IL-32 promoter SNP genotypes. (A) mRNA expression of IL-32β in PBMCs from healthy individuals versus RA patients in unstimulated PBMCs (n = 7 healthy individuals; n = 22 RA patients). (B) mRNA expression of IL-32γ in PBMCs from RA patients and healthy individuals in unstimulated PBMCs (n = 7 healthy individuals; n = 22 RA patients). (C) mRNA expression of IL-32β in unstimulated PBMCs or PBMCs stimulated with rhTNFα from RA patients versus healthy individuals with the CC- versus TT-genotype for the IL-32 promoter SNP (n = 13 TT; n = 9 CC RA patients). (D) mRNA expression of IL-32γ in unstimulated PBMCs or PBMCs stimulated with rhTNFα from RA patients versus healthy individuals with the CC- versus TT-genotype for the IL-32 promoter SNP (n = 13 TT; n = 9 CC RA patients).

Back to article page